Comparison of Assisted Reproductive Technology Cycle Outcomes Among Daily Buserelin, Daily, and Every Other Day Triptorelin in Infertile Patients Referring to Imam Khomeini Hospital Complex: A Randomized Controlled Trial

Objectives: Different types of gonadotropin-releasing hormone (GnRH) agonist protocols are used in assisted reproductive technology (ART) cycles although the role of every other day GnRH agonist administration is not well understood.Thus, this study compared the effectiveness of different ways of the administration of GnRH agonists in the ovarian stimulation long protocol and their effects on in vitro fertilization (IVF) outcomes.Materials and Methods: In a randomized controlled trial (RCT), 138 patients were randomly assigned to 3 groups with 46 patients.In group A, patients were treated with daily buserelin 0.5 mg subcutaneously and those in group B were treated with triptorelin 0.1 mg daily, and finally, patients in group C received triptorelin 0.1 mg every other day (all under a long protocol).Eventually, controlled ovarian stimulation was performed with the follicle-stimulating hormone (FSH).Results: There was no significant difference in biochemical and clinical pregnancy, along with abortion and twin rates between the comparison groups.Meanwhile, the number of gonadotropin injections was significantly lower in group C (P = 0.033).Moreover, the number of follicles and days of ovarian stimulation did not have a significant difference between study groups.Finally, the number of metaphase 2 oocytes and embryos was significantly higher in group A (P = 0.001).Conclusions: In general, pregnancy and abortion rates did not significantly differ between the comparison groups and, the number of gonadotropin injections was significantly lower in the triptorelin 0.1 mg every other day group.Thus, our finding revealed that every other day use of triptorelin 0.1 mg, comparing its daily use or daily buserelin, might be cost-benefit.